Desmoid tumors: Need for an individualized approach

Expert Review of Anticancer Therapy

Volumn 9, Issue 4, 2009, Pages 525-535

  de Bree, Eelco ^a   Keus, Ronald ^c   Mellissas, John ^a   Tsiftsis, Dimitris ^a   van Coevorden, Fritz ^b  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^c Arnhems Radiotherapeutisch Instituut   (Netherlands)

Author keywords

Aggressive fibromatosis; Desmoid; Desmoid type fibromatosis; Etiology; Multimodality treatment; Radiotherapy; Risk factors; Surgery

Indexed keywords

ALPHA INTERFERON; APC PROTEIN; BETA CATENIN; COLCHICINE; CYCLOOXYGENASE 2; DACARBAZINE; DOXORUBICIN; IMATINIB; INDOMETACIN; MELOXICAM; METALLOPROTEINASE; PLATELET DERIVED GROWTH FACTOR; PREDNISOLONE; PROGESTERONE; SULINDAC; TAMOXIFEN; TESTOLACTONE; WARFARIN; ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 2 INHIBITOR;

CANCER CONTROL; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CELL PROLIFERATION; DESMOID TUMOR; DRUG MEGADOSE; HUMAN; LIMB PERFUSION; MULTIMODALITY CANCER THERAPY; PATHOGENESIS; PROGNOSIS; RADIATION DOSE; RADIATION DOSE FRACTIONATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SURGICAL WOUND; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT; ADJUVANT THERAPY; ADULT; AGE; CASE MANAGEMENT; CHILD; FEMALE; FIBROMATOSIS; MALE; PATHOLOGY; PATIENT REFERRAL; PREGNANCY; PREGNANCY COMPLICATION; RADIOTHERAPY; TUMOR RECURRENCE;

ADULT; AGE FACTORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CASE MANAGEMENT; CHILD; COMBINED MODALITY THERAPY; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; FIBROMATOSIS, AGGRESSIVE; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC; RADIOTHERAPY; RADIOTHERAPY, ADJUVANT; REFERRAL AND CONSULTATION; RISK FACTORS;

EID: 67650299627     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/ERA.09.9     Document Type: Review

References (89)

1. de Bree E, Zoetmulder FAN, Keus RB et al. Plantar fibromatosis: incidence and treatment of recurrences by surgery and postoperative radiotherapy. Am. J. Surg. 187, 33-38 (2004).
2. Reitamo JJ, Scheinin TM, Hayry P. The desmoid syndrome: new aspects in the cause, pathogenesis and treatment of the desmoid tumor. Am. J. Surg. 151, 230-237 (1986).
3. Muller J. Über Den Feinern Bau Und Die Formen Der Krankenhaften Gachwulste. Reimer G (Ed.). Berlin, Germany 1-60 (1838).
4. Papagelopoulos PJ, Mavrogenis AF, Mitsiokapa EA et al. Current trends in the management of extra-abdominal desmoid tumours. World J. Surg. Oncol. 4, 21 (2006).
5. Sakorafas GH, Nissotakis C, Peros G. Abdominal desmoid tumors. Surg. Oncol. 16, 131-142 (2007).
6. Levefre JH, Parc Y, Kerneis S et al. Risk factors for development of desmoid tumours in familial adenomatous polyposis. Br. J. Surg. 95, 1136-1139 (2008).
7. Lee JC, Thomas JR, Phillips S et al. Aggressive fibromatosis: MRI features with pathologic correlation. Am. J. Roentgenol. 186, 274-254 (2006).
8. Mendenhall WM, Zlotecki RA, Morris CG et al. Aggressive fibromatosis. Am. J. Clin. Oncol. 28, 211-215 (2005).
9. Shields CJ, Winter DC, Kirwan WO, Redmond HP. Desmoid tumours. Eur. J. Surg. Oncol. 27, 701-706 (2001).
10. Soravia C, Berk T, McLeod RS, Cohen Z. Desmoid disease in patients with familial adenomatous polyposis. Dis. Colon Rectum 43, 363-369 (2000).
11. Alman BA, Pajerski ME, Diaz-Cano S et al. Aggressive fibromatosis (desmoid tumour) is a monoclonal disorder. Diagn. Mol. Pathol. 6, 98-101 (1997).
12. Li M, Cordon-Cardo C, Gerald WJ, Rosai J. Desmoid fibromatosis is a clonal process. Human Pathol. 27, 939-943 (1996).
13. Gurbuz AK, Giardiello FM, Petersen GM et al. Desmoid tumours in familial adenomatous polyposis. Gut 35, 377-381 (1994).
14. Nieuwenhuis MH, de Vos tot Nederveen Cappel W, Botma A et al. Desmoid tumors in a Dutch cohort of patients with familial adenomatous polyposis. Clin. Gastroenterol. Hepatol. 6, 215-219 (2008).
15. Alman BA, Li C, Pajerski ME, Diaz-Cano S, Wolfe HJ. Increased β catenin and somatic APC mutations in sporadic aggressive fibromatosis (desmoid tumors). Am. J. Pathol. 151, 329-334 (1997).
16. Li C, Bapat B, Alman BA. Adenomatous polyposis coli gene mutation alters proliferation though catenin regulatory function in aggressive fibromatosis (desmoid tumour). Am. J. Pathol. 153, 709-714 (1998).
17. Miyoshi Y, Iwao K, Nawa G et al. Frequent mutations in the β-catenin gene in desmoid tumors from patients without familial adenomatous polyposis. Oncol. Res. 10, 591-594 (1998).
18. Tejpar S, Nollet F, Li C et al. Predominance of β-catenin mutations and β-catenin deregulation in sporadic aggressive fibromatosis (desmoid tumor). Oncogene 18, 6615-6620 (1999).
19. Cheon SS, Cheah AY, Turley S et al. β-catenin stabilization dysregulates mesenchymal cell proliferation, motility, and invasiveness and causes aggressive fibromatosis and hyperplastic cutaneous wounds. Proc. Natl Acad. Sci. USA 99, 6973-6978 (2002).
20. Poon R, Smits R, Li C et al. Cyclooxygenase-two (COX-2) modulates proliferation in aggressive fibromatosis (desmoid tumor). Oncogene 20, 451-460 (2001).
21. Signori S, Frattinin M, Negri T et al. Cydooxygenase-2 and platelet-derived growth factor receptors as potential targets in treating aggressive fibromatosis. Clin. Cancer Res. 13, 5034-5040 (2007).
22. Kotiligam D, Lazae AJ, Pollock RE, Lev D. Desmoid tumor: a disease opportune for molecular insights. Histol. Histopathol. 23, 117-126 (2008).
23. Kong Y, Poon R, Nadesan P et al. Matrix metalloproteinase activity modulates tumor size, cell motility, and cell invasiveness in murine aggressive fibromatosis. Cancer Res. 64, 5795-5803 (2004).
24. Tolg C, Poon R, Fodde R et al. Genetic deletion of receptor for hyaluronan-mediated motility (Rhamm) attenuates the formation of aggressive fibromatosis (desmoid tumor). Oncogene 22, 6873-6882 (2003).
25. Muller E, Catsagnaro M, Yandel DW, Wolfe HJ, Alman BA. Molecular genetic and immunohistochemical analysis of tumour suppressor genes Rb and p53 in palmar and aggressive fibromatosis. Diagn. Mol. Pathol. 5, 194-200 (1996).
26. Clark SK, Neale KF, Landgrebe JC, Phillips RKS. Desmoid tumours complicating familial adenomatous polyposis. Br. J. Surg. 86, 1185-1189 (1999).
27. Smith AJ, Lewis JJ, Merchant NB, Leung DHY, Woodruff JM, Brennan MF. Surgical management of intra-abdominal desmoid tumours. Br. J. Surg. 87, 608-613 (2000).
28. Gega M, Yanagi H, Yoshikawa R et al. Successful chemotherapeutic modality of doxorubicin plus dacarbazine for the treatment of desmoid tumors in association with familial adenomatous polyposis. J. Clin. Oncol. 24, 102-105 (2006).
29. Bonvalot S, Eldweny H, Haddad V et al. Extra-abdominal primary fibromatosis: aggressive management could be avoided in a subgroup of patients. Eur. J. Surg. Oncol. 34, 462-468 (2008).
30. Bertagnolli MM, Morgan JA, Fletcher CDM et al. Multimodality treatment of mesenteric desmoid tumors. Eur. J. Cancer 44, 2404-2410 (2008).
31. Church JM. Desmoid tumors in patients with familial adenomatous polyposis. Semin. Colon Rectal Surg. 6, 29-32 (1995).
32. Baumert BG, Spahr MO, von Hochstetter A et al. The impact of radiotherapy in the treatment of desmoid tumours. An international survey of 110 patients. A study of the Rare Cancer Network. Radiation Oncol. 2, 12 (2007).
33. de Bree E, van Coevorden F, Keus RB, Tsiftsis DD. Treatment of extremity desmoid tumours. Eur. J. Surg. Oncol. 30, 1141-1142 (2004).
34. Abbas AE, Deschamps C, Cassivi SD et al. Chest wall desmoid tumors: results of surgical intervention. Ann. Thorac. Surg. 78, 1219-1223 (2004).
35. Phillips SR, A'Hern RA, Thomas JM. Aggressive fibromatosis of the abdominal wall, limbs and limb girdles. Br. J. Surg. 91, 1624-1629 (2004).
36. Pignatti G, Barbanti-Brodano G, Ferrari D et al. Extraabdominal desmoid tumor. A tudy of 83 cases. Clin. Orthop. Rel. Res. 375, 207-213 (2000).
37. Sørensen A, Keller J, Nielsen OS, Jensen OM. Treatment of aggressive fibromatosis. A retrospective study of 72 patients followed for 1-27 years. Acta Orthop. Scand. 73, 213-219 (2002).
38. Lev D, Kotilingam D, Wei C et al. Optimizing treatment of desmoid tumors. J. Clin. Oncol. 25, 1785-1791 (2007).
39. Ballo MT, Zagars GK, Pollock A et al. Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. J. Clin. Oncol. 17, 158-167 (1999).
40. Spear MA, Jennings LC, Mankin HJ et al. Individualizing management of aggressive fibromatosis. Int. J. Radiat. Oncol. Biol. Phys. 40, 637-645 (1998).
41. Melis M, Zagar JS, Sondal VK. Multimodality management of desmoid tumors: how important is a negative surgical margin? J. Surg. Oncol. 98, 594-602 (2008).
42. Guadagnolo BA, Zagars GK, Ballo MT. Long-term outcomes for desmoid tumors treated with radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 71, 441-447 (2008).
43. Zlotecki RA, Scarborough MT, Morris CG et al. External beam radiotherapy for primary and adjuvant management of aggressive fibromatosis. Int. J. Radiat. Oncol. Biol. Phys. 54, 177-181 (2002).
44. Nuyttens JJ, Rust PF, Thomas CR Jr, Turrisi AT III. Surgery versus radiation therapy for patients with aggressive fibromatosis or desmoid tumors. A comparative review of 22 articles. Cancer 88, 1517-1523 (2000).
45. Gronchi A, Casali PG, Mariani L et al. Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution. J. Clin. Oncol. 21, 1390-1397 (2003).
46. Micke O, Seegenschmiedt MH; the German Cooperative group on Radiotherapy for Benign Diseases. Radiation therapy for aggressive fibromatosis (desmoids tumors): results of a national patterns of care study. Int. J. Radiat. Oncol. Biol. Phys. 61, 882-891 (2005).
47. Faulkner LB, Hajdu SI, Kher U et al. Pediatric desmoid tumor: retrospective analysis of 63 cases. J. Clin. Oncol. 13, 2813-2818 (1995).
48. Merchant NB, Lewis JJ, Woodruff JM et al. Extremity and trunk desmoid tumors. A multifactorial analysis of outcome. Cancer 86, 2045-2052 (1999).
49. Stoeckle E, Coindre JM, Longy M et al. A critical analysis of treatment strategies in desmoid tumours: a review of a series of 106 patients. Eur. J. Surg. Oncol. 35, 129-134 (2009).
50. Church J, Lynch C, Neary P et al. A desmoid tumor staging system separates patients with intra-abdominal, familial adenomatous polyposis-associated desmoid disease by behavior and prognosis. Dis. Colon Rectum 51, 897-901 (2008).
51. Buitendijk S, van de Ven CP, Dumans TG et al. Pediatric aggressive fibromatosis. A retrospective analysis of 13 patients and review of the literature. Cancer 104, 1090-1099 (2005).
52. Leithner A, Gapp M, Leithner K et al. Margins in extra-abdominal desmoids tumors: a comparative analysis. J. Surg. Oncol. 86, 152-156 (2004).
53. Cheon SS, Nadesan P, Poon R et al. Growth factors regulate β-catenin mediated TCF-dependent transcriptional activation in fibroblasts during the proliferative phase of wound healing. Exp. Cell Res. 293, 267-274 (2004).
54. Posner MC, Shiu MH, Newsome JL et al. The desmoid tumors: not a benign disease. Arch. Surg. 124, 191-196 (1989).
55. Lewis JJ, Boland PJ, Leung DHY, Woodruff JM, Brennan MF. The enigma of desmoid tumors. Ann. Surg. 229, 866-872 (1999).
56. Chatzipetrou MA, Tzakis AG, Pinna AD et al. Intestinal transplantation for the treatment of desmoid tumors associated with familial adenomatous polyposis. Surgery 129, 277-281 (2001).
57. Calne RY, Pollard SG, Jamieson NV. Intestinal transplant for recurring mesenteric desmoid tumour. Lancet 342, 58-59 (1993).
58. Morris JA, Johnson DL, Ripper JAP et al. Identical-twin small-bowel transplant for desmoid tumour. Lancet 345, 1577-1578 (1995).
59. Ballo MT, Zagars GK, Pollack A. Radiation therapy in the management of desmoid tumors. Int. J. Radiat. Oncol. Biol. Phys. 42, 1007-1014 (1998).
60. Keus R, Bartelink H. The role of radiotherapy in the treatment of desmoid tumors. Radiother. Oncol. 7, 1-5 (1986).
61. Schmitt G, Mills EED, Levin V et al. Radiotherapy of aggressive fibromatosis. Eur. J. Cancer 28A, 832-835 (1992).
62. Merchant TE, Nguyen D, Walter AW et al. Long-term results with radiation therapy for pediatric desmoids tumors. Int. J. Radiat. Oncol. Biol. Phys. 47, 1276-1271 (2000).
63. Chew C, Reid R, O'Dwyer PJ. Evaluation of the long term outcome of patients with extremity desmoids. Eur. J. Surg. Oncol. 30, 428-432 (2004).
64. de Bree E, Keus R, van Coevorden F. Risk factors for local control failure of desmoid tumours. Eur. J. Surg. Oncol. 24, 986 (2008).
65. Janinis J, Patriki M, Vini L, Aravantinos G, Whelan JS. The pharmacological treatment of aggressive fibromatosis: a systemic review. Ann. Oncol. 14, 181-190 (2003).
66. Tsukada K, Church JM, Jagelman DG et al. Noncytotoxic drug therapy for intra-abdominal desmoid tumor in patients with familial adenomatous polyposis. Dis. Colon Rectum 35, 29-33 (1992).
67. Waddell WR, Kirsch WM. Testolactone, sulindac, warfarin, and vitamine K1 for unresectable desmoid tumors. Am. J. Surg. 161, 416-421 (1991).
68. Nakada I, Ubukata H, Goto Y et al. Prednisolone therapy for intra-abdominal desmoid tumors in a patient with familial adenomatous polyposis. J. Gastroenterol. 32, 255-259 (1997).
69. Hansmann A, Adolph C, Vogel T, Unger A, Moeslein G. High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors. Cancer 100, 612-620 (2004).
70. Dominiguez-Malagon HR, Alfeiran-Ruiz A, Chavarria-Xicotencatl P, Duran-Hernadez MS. Clinical and cellular effects of colchicine in fibromatosis. Cancer 69, 2478-2483 (1992).
71. Deyrup AT, Tretiakova M, Montag AG. Estrogen receptor-β expression in extra abdominal fibromatosis: an analysis of 40 cases. Cancer 106, 208-213 (2006).
72. Okuno SH, Edmonson JH. Combination chemotherapy for desmoid tumors. Cancer 97, 1134-1135 (2003).
73. Tsukada K, Church JM, Jagelman DG, Fazio VW, Lavery IC. Systemic cytotoxic chemotherapy and radiation therapy for desmoid in familial adenomatous polyposis. Dis. Colon Rectum 34, 1090-1092 (1991).
74. Skapek SX, Ferguson WS, Granowetter L et al. Vinblastine and methotrexate for desmoid fibromatosis in children; results of a Pediatric Oncology Group Phase II trial. J. Clin. Oncol. 25, 501-506 (2007).
75. Baliski CR, Temple WJ, Arthur K, Schachar NS. Desmoid tumors: a novel approach for local control. J. Surg. Oncol. 80, 96-99 (2002).
76. Mace J, Biermann JS, Sondak V et al. Response of extraabominal desmoid tumors to therapy with imatinib mesylate. Cancer 95, 2373-2379 (2002).
77. Heinrich MC, McArthur GA, Demetri GD etal. Clinical and molecular studies of the effect of Imatinib on advanced aggressive fibromatosis (desmoid tumor). J. Clin. Oncol. 24, 1195-1203 (2006).
78. Heinrich MC, Joensuu H, Demetri GD et al. Phase II, open-label study evaluating the activity in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin. Cancer Res. 14, 2717-2725 (2008).
79. Wcisio G, Szarlej-Wcisio K, Szczylik C. Control of aggressive fibromatosis by treatment with imatinib mesylate. A case report and review of the literature. J. Cancer Res. Clin. Oncol. 133, 533-558 (2007).
80. Goncalves A, Monges G, Yang Y et al. Response of a KIT-positive extra-abdominal fibromatosis to imatinib mesylate and KIT genetic analysis. J. Natl Cancer Inst. 98, 562-563 (2006).
81. Liegl B, Leithner A, Bauernhofer T et al. Immunohistochemical and mutational analysis of PDGF and PDGFR in desmoid tumours: is there a role for tyrosine kinase inhibitors in c-kit-negative desmoid tumours? Histopathology 49, 576-581 (2006).
82. Lev-Chekouche D, Abu-Abeid S, Nakache R et al. Limb desmoid tumors: a possible role for isolated limb perfusion with tumor necrosis factor-α and melphalan. Surgery 126, 963-967 (1999).
83. Grünhagen DJ, de Wilt JHW, Verhoef C et al. TNF-based isolated limb perfusion in unresectable extremity desmoid tumours. Eur. J. Surg. Oncol. 31, 912-916 (2005).
84. Gutierez JC, Perez EA, Moffat FL et al. Should soft tissue sarcomas be treated at high-volume centres? An analysis of 4205 patients. Ann. Surg. 245, 952-958 (2007).
85. Purdy JA. Dose to normal tissues outside the radiation therapy patient's treated volume: a review of different radiation therapy techniques. Health Phys. 95, 666-676 (2008).
86. Takemaru KI, Ohmitsu M, Li FQ. An oncogenic hub: β-catenin as a molecular target for cancer therapeutics. Handb. Exp. Pharmacol. 186, 261-284 (2008).
87. Bright-Thomas RM, Agrawal A, Hargest R. Preclinical studies of gene transfer for the treatment of desmoid disease in familial adenomatous polyposis. Br. J. Surg. 89, 1563-1569 (2002).
88. Castellazzi G, Vanel D, Le Cesne A et al. Can the MRI signal of aggressive fibromatosis be used to predict its behavior? Eur. J. Radiol. 69, 222-229 (2009).
89. Lazar AJ, Tuvin D, Hajibashi S et al. Specific mutations in the β-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am. J. Pathol. 173, 1518-1527 (2008).